A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Inebilizumab (Primary) ; Corticosteroids; Immune globulin; Methylprednisolone
Indications Anti-N-methyl-D-aspartate-receptor-encephalitis
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms ExTINGUSH

06 Sep 2022 Planned End Date changed from 30 Aug 2026 to 31 Aug 2026.
06 Sep 2022 Planned primary completion date changed from 1 Oct 2025 to 31 Oct 2025.
22 Aug 2022 Planned End Date changed from 1 Apr 2026 to 30 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com